![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 40, 37711-37717, October 4, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
¶
From the Departments of
Pharmaceutics and
§ Zoology, University of Washington, Seattle, Washington
98195
Received for publication, May 21, 2002, and in revised form, June 22, 2002
| |
ABSTRACT |
|---|
|
|
|---|
To test the hypothesis that human concentrative
and equilibrative nucleoside transporters (hCNT1 and hENT1) are present
on the apical and basolateral membrane, respectively, we constructed a
Madin-Darby canine kidney (MDCK) cell line that simultaneously and
stably expresses recombinant hCNT1 and hENT1 gene products tagged with
CFP and YFP fluorescent proteins, respectively. Using a confocal
microscope, both hCNT1-CFP and hENT1-YFP were found to be distributed
uniformly on the plasma membrane of undifferentiated MDCK cells. Upon
differentiation of the MDCK cells on Transwell filter inserts,
hCNT1-CFP was visualized exclusively on the apical membrane, whereas
hENT1-YFP appeared predominantly on the basolateral membrane. As
differentiation proceeded, there was an increase in alkaline
phosphatase activity, and activity of hENT1 in the apical compartment
decreased while hCNT1 activity remained constant. These results suggest
that, on differentiation, hENT1 is sorted to the basolateral membrane.
This was confirmed when the hCNT1-mediated uptake of
[3H]uridine from the apical compartment of the
differentiated cells was found to be ~20-fold higher and that for
hENT1 was ~4-fold lower than the corresponding uptake from the basal
compartment. As observed in vivo, the net transport of
[3H]adenosine was from the apical to the basal
compartment, whereas that for 14C-deoxyadenosine was from
the basal to the apical compartment. In summary, we have shown for the
first time that hCNT1 and hENT1 are expressed in polarized MDCK cells
on the apical and basolateral membrane, respectively, allowing
vectorial transport in both directions depending on the relative
activity (ratio of maximal transporter activity to affinity) of each
transporter for their substrates.
Nucleoside transporters
(NTs)1 are important in
mediating the transport of nucleosides and nucleoside drugs
(e.g. antiviral and anticancer drugs) across cell membranes
(1). Physiologically, the sodium-dependent concentrative
nucleoside transporters mediate the influx of nucleosides. Human
concentrative nucleoside transporter 1 (hCNT1) is
pyrimidine-specific, whereas hCNT2 is purine-specific. Both hCNT1 and
hCNT2 transport uridine and adenosine (2) and are insensitive to
inhibition by nitrobenzylthioinosine (NBMPR). hCNT1 and hCNT2 are
expressed on specialized cells such as intestine and kidney epithelia
(3, 4). The equilibrative transporters mediate both the influx and
efflux of nucleosides and exhibit broad substrate specificity,
accepting both purine and pyrimidine nucleosides as permeants. Human
equilibrative nucleoside transporter 1 (hENT1 or es)
is inhibited by NBMPR concentrations as low as 0.1 nM (IC50
~0.4 nM), whereas hENT2 (ei) transporter is
insensitive to inhibition as high as 1 µM
(IC50 ~2.8 µM) (1, 4, 5). One or both of
the equilibrative transporters are expressed in most, if not all, cell types.
Although functional measurement of transporter activity has helped
elucidate the tissue expression of the concentrative and equilibrative
nucleoside transporters, because of the lack of antibodies little
information is available on the cellular localization of these
transporters. Functional studies using membrane vesicles have shown
that the concentrative transporters are found only on the apical
membrane of the polarized epithelial cells (3, 6, 7). In contrast, such
studies have resulted in controversial findings regarding the membrane
localization of the equilibrative transporters. For example, we have
shown that the equilibrative nucleoside transporters, hENT1 and hENT2,
are absent from the apical membrane of the human enterocytes (3) and we
have hypothesized that they are present on the basolateral membranes
(8). In contrast, others have found ENT1 (but not ENT2) to be present on the apical membrane (9) or on both membranes (10) of the polarized
epithelial cells. Because of the lack of availability of antibodies for
immunolocalization of the equilibrative transporters, it has been
difficult to resolve this controversy. To test the hypothesis that the
concentrative and equilibrative nucleoside transporters are present on
different faces of the polarized epithelial cells, we have used the
model epithelial cell line derived from the kidney, namely the MDCK
cells. We constructed a stable MDCK cell line that simultaneously
expresses recombinant hCNT1 and hENT1 gene products tagged with CFP and
YFP fluorescent proteins, respectively. These cells were then used to
test the localization of these two transporters in both the
nonpolarized and polarized MDCK cells. In addition, we tested the
hypothesis that the directionality of vectorial transport of
nucleosides across polarized cells will depend on the localization and
activity (Vmax/Km) of these
nucleoside transporters for their substrates. Specifically, we asked
whether differential localization of hCNT1 and hENT1 could explain the
paradoxical observation in vivo that adenosine is actively
reabsorbed by the human kidney, whereas deoxyadenosine is secreted.
Gene Construction--
A 1.4-kb human intestinal ENT1 (hENT1)
and a 2.0-kb CNT1 (hCNT1) fragment was amplified from the plasmid
constructed previously (11) using primer pairs overlapping the start or
end codons. BglII and KpnI sites were added as
follows: hENT1, sense (TGATGAAGATCTATGACAACCAGTCACCAGC) and antisense
(TAGTAGGGTACCTCACACAATTGCCCGGAACA); hCNT1, sense (TGATGAAGATCTATGGAGAACGACCCCTCGAG) and antisense
(TAGTAGGGTACCTCACTGTGCACAGATCGTGT). The fragment was subcloned into
BglII and KpnI sites of the yellow fluorescence
vector pEYFP-C1 or cyan fluorescence vector pECFP-C1 (CLONTECH, Palo Alto, CA). The resulting
constructs, hENT1-YFP and hCNT1-CFP, were used to produce a stable MDCK
cell line expressing hENT1 and hCNT1. All constructs were confirmed by
automated sequence analysis using BigDye terminator cycle sequencing
ready reaction kits (PE Applied Biosystems, Foster City, CA). To
construct expression plasmids without tagged fluorescence protein,
hENT1-YFP and hCNT1-CFP constructs were double-digested with
AgeI and BglII. A 5.4- (hENT1) or 6.0-kb (hCNT1)
fragment was isolated and ligated after blunting the cutting end to
yield hENT1-pE and hCNT1-pE expression cassettes.
Selection of MDCK Cells Stably Coexpressing hCNT1 and
hENT1--
MDCK cells were cultured in minimum Eagle's medium
with Earle's salts and L-glutamine containing 10% fetal
bovine serum, 100 units of penicillin, and 100 µg/ml streptomycin
(Invitrogen) at 37 °C in 95% air, 5% CO2 with
95% humidity. To generate stable hCNT1 and hENT1 transfectants,
~7 × 105 cells/well were seeded in six-well plates
in minimum Eagle's medium 1 day before transfection. The expression
cassettes were transfected using LipofectAMINE 2000 (Invitrogen)
according to the manufacturer's instructions. Briefly, 2.5 µg of the
hENT1-YFP and 2.5 µg of the hCNT1-CFP constructs were diluted in 0.25 ml of Dulbecco's modified Eagle's medium without serum and mixed with
15 µl of LipofectAMINE 2000 reagent diluted in 0.25 ml of Dulbecco's
modified Eagle's medium without serum. Then the mixture was incubated
for 30 min at room temperature. The mixture was applied to MDCK cells
maintained in a six-well plate at ~90% confluence. Forty-eight hours
later, the cells were transferred to a 100-mm dish and cultured in
growth medium containing G418 (Invitrogen). The medium was changed
every 3 days, and the G418 concentration was varied from 200 to 1000 µg/ml depending on the status of the cells. After selection for 2 to
3 weeks, cell colonies were isolated using cloning cylinders by
checking their fluorescence intensity using a fluorescence microscope
(Zeiss, Thornwood, NY). Cells highly expressing both CFP and YFP were
subsequently cloned on 96-well plates using limited cell dilution.
Uridine Uptake Experiments--
All uptake experiments were
carried out in triplicate in sodium-containing transport buffer
(Tris-HCl 20 mM, K2HPO4 3 mM, MgCl2.6 H2O 1 mM,
CaCl2 2 mM, glucose 5 mM, NaCl 130 mM, pH 7.4) or sodium-free transport buffer in which NaCl
was replaced by N-methy-D-glucamine 130 mM (pH 7.4). The uptake experiments were conducted 3 days
after seeding in 24-well plates. To measure
sodium-dependent uptake, the cells were washed three times
with sodium-free buffer and preincubated with sodium-free buffer with
10 µM NBMPR (in 0.1% Me2SO) for 15 min at 37 °C. Then 0.5 ml of sodium transport buffer or sodium-free
buffer containing 1 µM [3H]uridine
(1 µCi/ml, 17.7 Ci/mmol, Moravek Biochemicals, Brea, CA) and
10 µM NBMPR were added to each well. To measure
Na+-independent facilitative uptake, the cells were washed
three times with sodium-free buffer and preincubated with sodium-free buffer with or without 10 µM NBMPR for 15 min. Then 0.5 ml of sodium-free buffer containing 1 µM
[3H]uridine with or without 10 µM NBMPR was
added to the wells. To control for any solvent effect, an equal
amount of Me2SO was included in all experiments. After
incubating at 37 °C for 5, 10, or 15 min, the wells were washed
rapidly three times with ice-cold Na+-free buffer
containing 10 µM NBMPR. The cells were solubilized with
0.5 ml of 1 N NaOH and then neutralized with 0.5 ml of 1 N HCl. Then 0.8 ml of the cell lysate was counted on the
scintillation counter. Protein in the cell homogenate was quantified
using the BCA protein assay kit (Pierce). Bovine serum albumin was used to generate a standard curve to determine the protein concentration. Nucleoside transporter-mediated uridine uptake was calculated as the
difference between the uptake by the MDCK cell transfected with hCNT1
and hENT1 cDNAs and the uptake by mock-transfected cells.
Transwell Transport Experiments--
1 × 105
stable coexpressing cells were seeded on six-well polycarbonate
Transwell filter inserts (Corning Costar Quality Biological, Gaithersburg, MD) and cultured with regular changes of medium for
10-12 days after reaching confluence. To ensure that the cells had
polarized and formed tight junctions, transport experiments were
conducted when the transepithelial electrical resistance (TEER) values
(measured by millicell-ERS; Millipore, Bedford, MA) reached 300-500
ohms/cm2 in representative wells. The Transwell filter
inserts were washed three times with Na+-free buffer, and
then 1 µM [3H]uridine was added to either
the apical or the basal side. At various times, 50 µl of buffer was
collected from the opposite compartment, either apical or basal.
The transport experiments were terminated by aspirating the buffer, and
filters were washed with chilled Na+-free buffer containing
10 µM NBMPR. The whole filter was wiped with tissue to
remove any excess buffer, the filter was removed from the plastic
support, and the filter was counted on a scintillation counter.
Visualization of hCNT1 and hENT1 Tagged with Fluorescence
Proteins--
1 × 106 stable coexpressing cells were
grown in either two-well Lab-Tek borosilicated coverglass chambers
(Nalge Nunc International Corp., Naperville, IL) or six-well Corning
Costar polycarbonate Transwell filter inserts for 10-12 days after
reaching confluence. The filters were washed with phosphate-buffered
saline, excised, then loaded on a glass slide and covered with a
coverslip. Between the slide and the coverslip, an ~1-mm gap was
filled with medium to keep the cells alive. Images were obtained using
a Leica TCS NT laser-scanning confocal microscope equipped with a
krypton/argon laser as the light source. Images were captured by
excitation at 458 nm and emission at 470-480 nm (CFP) or excitation at
488 nm and emission at 610-640 nm (YFP).
Measurement of Alkaline Phosphatase Activity, a Marker of Cell
Differentiation--
Alkaline phosphatase activity was measured at 410 nM in 75 mM alkaline buffer solution (pH 10.3, Sigma). The confluent monolayers in 24-well plates were washed twice
with buffer solution. Then a buffer containing 6 mM
4-nitrophenylphosphate was added to the confluent monolayers. The
buffer was then removed from the culture wells after 15 min to measure
the liberated 4-nitrophenol at 410 nM using a
spectrophotometer. p-Nitrophenol (Sigma) was used to generate a standard curve. The data were expressed as
µmol/p-nitrophenol/min/cm2 filter.
Vectorial Transport of [3H]Adenosine and
14C-Deoxyadenosine by MDCK Monolayer Cells Grown on
Transwell Filters--
hENT1-YFP and hCNT1-CFP coexpressing and mock
cells were seeded on six-well polycarbonate Transwell filter inserts
and cultured for 10-12 days with a regular change of medium. Transport
experiments were conducted when the transepithelial electrical
resistance reached 300-500 ohms/cm2 in a representative
well. The filter inserts were washed three times and preincubated with
500 µM adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride for 30 min. Then 8 µM [3H]adenosine (32.1 Ci/mmol,
Moravek Biochemicals) and 8 µM
[14C]deoxyadenosine (56 mCi/mmol, American Radiolabled
Chemicals, Inc., St. Louis, MO) were loaded in the basal or apical
compartment of the Transwell filter inserts. Transport experiments were
conducted with buffer (1.0 ml in the apical compartment and 1.5 ml in
the basal compartment) containing sodium but not NBMPR on both
sides of the Transwell filters. Fifty µl of buffer from the
compartment opposite the loading side were sampled at various times (up
to 60 min), and the buffer was replenished immediately. At the
end of the experiments, the filters were washed and removed from
plastic supports to measure the cell contents of adenosine and
deoxyadenosine. The cells on the filters were solubilized by 0.3 ml of
1 N NaOH and then neutralized by 0.3 ml of 1 N
HCl. Radioactivity was counted using a dual channel scintillation counter.
HPLC Analysis--
To determine the maximum possible metabolism
of [3H]adenosine and [14C]deoxyadenosine
under the above described transport conditions, the above experiment
was repeated for 60 min on a separate batch of cells. Buffer
samples from the loading and the contralateral compartments were
collected, and cells on the filters were sonicated in the presence of 1 ml of methanol and then centrifuged at 700 × g for 15 min. The cell lysates were diluted twice with water. Fifty-µl samples
were injected onto a C18 HPLC column (Econosil, 250 × 4.6 mm, 5 µ, Alltech Associates, Inc., Deerfield, IL). The column was
eluted with a mobile phase consisting of 20% methanol and 80% water
(0.8 ml/min). The HPLC effluent was collected every 30-60 s for 30 min
and counted using a dual channel scintillation counter. Elution times
of adenosine and deoxyadenosine were confirmed by injection of cold
standards and detection at 254 nm.
Data Analysis--
Data are expressed as the mean ± S.D.
of uptake values obtained in three wells or filter inserts. Data are
representative of a minimum of two experiments carried out on different
days on different batches of cell.
We chose to use MDCK cells for expression of human nucleoside
transporters for several reasons. First, they readily express heterologous proteins. Second, the cells can be readily differentiated into polarized cells, allowing the study of localization of nucleoside transporters in the undifferentiated and differentiated cells. Third,
these cells have been studied extensively in the past to determine
localization and mechanisms of sorting of numerous other membrane proteins.
To conveniently and simultaneously detect the localization of both
hCNT1 and hENT1 in polarized MDCK cells, we constructed cyan and yellow
fluorescence fusion proteins of these gene products. Cells expressing
individual proteins were used to confirm that there was no overlap in
the emission signal between YFP and CFP (data not shown). Localization
of hCNT1 and hENT1 in undifferentiated MDCK cells was visualized by
confocal microscopy. CFP-tagged hCNT1 and YFP-tagged hENT1 exhibited an
even distribution on the plasma membrane of the cell (Fig. 1,
A and B). In cells
expressing both proteins, their areas of localization overlapped
(Fig 1C). In contrast, expression of the empty YFP vector
showed diffuse localization in the entire cell (Fig.
1D).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (156K):
[in a new window]
Fig. 1.
Coexpression of hENT1-YFP and
hCNT1-CFP in MDCK cells. The coexpressing cells were seeded on a
Lab-Tek chambered coverglass and visualized with a confocal microscope.
hCNT1-CFP fluorescence (A) was detected by excitation
at 458 nm and collecting the emission at 460-470 nm, whereas hENT1-YFP
fluorescence (B) was detected by excitation at 488 nm and
collecting the emission at 600-630 nm. Both hCNT1-CFP and hENT1-YFP
are localized on the plasma membrane. C, merging of images
A and B shows that more than 90% of the cells
coexpress the two gene products. D, in contrast, MDCK cells
transfected with pEYFP empty vector (mock cells) showed diffuse
expression throughout the cells.
Because uridine is a substrate for both hCNT1 and hENT1, we used it in
our studies to quantify the functional activity of hCNT1 and hENT1
coexpressed in MDCK cells. When the cells are incubated in
Na+-free medium and 3H-labeled uridine, only
the equilibrative nucleoside transporter activity can be observed (Fig.
2A). At 15 min, hENT1 shows an almost 30-fold greater uptake of [3H]uridine in the
coexpressing cells than in the mock (vector only) cells. In the
presence of NBMPR (10 µM), which specifically inhibits hENT1 (but not hCNT1), almost all of the hENT1-mediated uptake of
[3H]uridine is inhibited, thus showing very clearly the
functional activity of hENT1 in these coexpressing cells. Similarly,
when the cells are incubated with Na+-containing buffer and
10 µM NBMPR, only hCNT1-mediated uptake of
[3H]uridine is observed (Fig. 2B). At 15 min,
hCNT1-mediated uptake of [3H]uridine by the coexpressing
cells is ~60-fold greater than that by mock cells. Mock cells
demonstrated low hENT-type activity, whereas hCNT1 activity was
absent. As previously shown by Mangravite et al. (12), we
found that [3H]uridine uptake by hCNT1 was comparable
with that by hCNT1-CFP. Likewise, [3H]uridine uptake by
hENT1 was similar to that by hENT1-YFP (data not shown). These results
demonstrate that both hENT1-YFP and hCNT1-CFP are functional when
simultaneously expressed in undifferentiated MDCK cells.
|
We used the doubly transfected MDCK cells to test the hypothesis that
hCNT1 and hENT1 are expressed on the apical and basolateral membrane,
respectively, of polarized epithelial cells, allowing vectorial
transport of nucleosides and nucleoside drugs from the apical
compartment to the basal compartment or vice versa. As described below,
our data show that this hypothesis is correct. Unlike in
undifferentiated cells, in the differentiated polarized MDCK cells the
localization of hCNT1 and hENT1 on the plasma membrane did not overlap.
In the x-y plane, hCNT1 is localized predominately on the
apical layer and hENT1 is localized
mostly on the layer adjacent to the filter (Fig.
3, A and B).
Indeed, vertical cross-sections of the images (z
plane) showed that hCNT1-CFP was found exclusively on the apical
membrane (Fig. 3D), whereas hENT1-YFP was distributed predominantly around the basolateral membrane (Fig. 3E). The
merged images of CFP and YFP confirmed this localization (Fig.
3F). As a control, MDCK cells transfected with the YFP empty
vector showed diffuse localization in the cell in both the
x-y and the z planes (Fig. 3, C and
G).
|
To confirm this differential localization functionally, we measured
both hCNT1 and hENT1 activity in the apical and basal compartment of
differentiated cells grown on Transwell filters. [3H]Uridine (1 µCi/ml, 0.2 µM) was loaded
on either the apical or the basal compartment. As measured by cellular
accumulation of uridine radioactivity, hENT1 activity in the apical
compartment was ~4-fold lower than in the basal compartment, whereas
hCNT1 activity in the apical compartment was ~20-fold greater than in the basal compartment (Fig. 4,
A and B). In contrast, in the mock cells, no
difference was observed in cellular accumulation of radioactivity
whether uridine was loaded on the apical or the basal compartment.
|
As the localization of hENT1 and hCNT1 in differentiated and
undifferentiated MDCK cells was different, we tested the
hypothesis that differentiation of MDCK cells results in sorting of
hENT1 to the basolateral compartment. To test this hypothesis, we
measured the time course of uptake of [3H]uridine by
hENT1 and hCNT1 when loaded in the apical compartment of MDCK cells
grown on 24-well plates. To measure the time course of differentiation
of these cells, alkaline phosphatase activity in the apical
compartment, a marker of differentiation, was also measured. The cells
began to differentiate at about 6-8 days from confluence and reached
complete differentiation at about 13 days from confluence. As cells
began to differentiate, the activity of hENT1 in the apical compartment
began to decrease and reached a minimum at about 13 days
after confluence (Fig. 5). Meanwhile the
apical uptake by hCNT1 remained relatively constant throughout the
entire experimental period. These results suggest that upon differentiation, hENT1 is sorted to the basolateral membrane of MDCK
cells. Somewhat different results have been obtained with the OK cells
(epithelium cells from the opossum kidney) (10). At day 10 from
confluence, both Na+-dependent and
Na+-independent endogenous transporter activity are
observed in the apical compartment, whereas only
Na+-independent activity is observed in the basal
compartment of these polarized cells. In contrast, at day 1 from
confluence (presumably nonpolarized cells), the majority of transporter
activity is Na+-independent (10). These data suggest that
in OK cells, on differentiation the concentrative transporter(s) sort
to the apical membrane, whereas the equilibrative transporter(s) are
present on both the apical and basolateral membrane.
|
We hypothesized that the differential localization of hCNT1 and hENT1
transporters and their activities in the polarized cells should affect
the directionality of vectorial transport of various nucleoside and nucleoside drugs across these cells. At subsaturating concentrations, this directionality of transport will be determined by
the relative ratio of the maximal transport activity
(Vmax) and the affinity (Km)
of the transporters for the nucleosides, provided the nucleoside is not
completely metabolized within the cells. Therefore, we tested the
hypothesis that this differential localization of nucleoside
transporters explains the paradoxical observation that adenosine and
deoxyadenosine are handled quite differently in vivo by the
kidney. In the presence of adenosine deaminase deficiency or an
adenosine deaminase inhibitor, adenosine is actively absorbed, whereas
deoxyadenosine is secreted (13-16). Indeed, as observed in
vivo, in the presence of an adenosine deaminase inhibitor,
adenosine is preferentially transported from the apical to the basal
compartment by the coexpressing polarized MDCK cells (Fig.
6, A and B),
whereas deoxyadenosine is preferentially transported from the basal to
the apical compartment (Fig. 6, A and B). At 60 min, there is a net A
B transport of adenosine and a net B
A
transport of deoxyadenosine (Fig. 6B). This preferential transport of adenosine is confirmed by its greater uptake from the
apical compartment when compared with deoxyadenosine (Fig. 6C). hCNT1 has a high affinity (Km, ~50
and 46 µM, respectively) for adenosine and deoxyadenosine
(17). However, transport of deoxyadenosine by hCNT1 is slower than that
of adenosine. The hCNT1-mediated adenosine-to-deoxyadenosine flux ratio
is 4:1 (17, 18). In contrast, adenosine and deoxyadenosine are
transported by hENT1 with about equal affinity (Km
60 and 71 µM respectively) (1). Thus, in coexpressing
MDCK cells, when adenosine and deoxyadenosine are placed in the apical
compartment, hCNT1 transports adenosine into the cells more efficiently
than deoxyadenosine. At 60 min the majority of adenosine is trapped in
the cells by metabolism (~95%; this and subsequent values of percent
metabolism were determined by HPLC), but a small percentage escapes
into the basal compartment (Fig. 6D). Of that which escape,
~65% is unchanged adenosine presumably transported by hENT1 (Fig.
6D) and 35% is metabolites (perhaps transported by
nucleotide efflux pumps). In contrast, at 60 min very little of the
deoxyadenosine radioactivity in the cells is metabolized (~10%)
(Fig. 6C), and the radioactivity of that which escapes to the basal compartment (Fig. 6D) is predominately
unchanged deoxyadenosine (~90%). When these two nucleosides are
introduced into the basal compartment, both adenosine and
deoxyadenosine are transported into the MDCK cells by hENT1 (Fig.
6C). Again, at 60 min, the greater part of the adenosine is
trapped intracellularly by metabolism (~95%) (Fig. 6C),
and a smaller portion, which escapes into the apical compartment by
diffusion or via the low level of hENT1 transporter present there, is
reabsorbed by hCNT1 present on the apical membrane (Fig.
6D). In contrast, at 60 min only a small amount of the
deoxyadenosine transported into the cells is trapped intracellularly by
metabolism (~15%) (Fig. 6C), whereas most of it is
eliminated (~85% deoxyadenosine) into the apical compartment either
by the low level of hENT1 transporter activity present there or by
diffusion (Fig. 6D). This differential localization of hCNT1
and hENT1 (Fig. 6E), with differing capacities to
transport adenosine and deoxyadenosine, appears to explain the
paradoxical observation that adenosine is reabsorbed, whereas
deoxyadenosine is secreted by the kidney in vivo. Although
the level of expression of hCNT1 and hENT1 in the human kidney may
differ from that in our doubly transfected MDCK cells, such a
difference will not change our general conclusions. This is because our
results are dependent primarily on the expression of both transporters
in series and on the relative transport
(Vmax/Km) of adenosine and
deoxyadenosine by each of the transporters, hCNT1 and hENT1. Only if
one or both of the transporters are saturated (or if one of the
transporters is absent) would our observed results change and differ
from those obtained in vivo. Indeed, the transporter on the
apical membrane of the kidney (presumably CNT1) can be saturated in the
perfused rat kidney by high concentrations of adenosine. In this event,
adenosine is secreted by the kidney and not actively reabsorbed (9).
The concentrations of adenosine and deoxyadenosine used in our
experiments (8 µM), are well below the
Km of adenosine and deoxyadenosine for hCNT1 (~50 and ~46 µM, respectively) or hENT1 (60 and 71 µM, respectively). At the physiological concentrations of
adenosine (<1 µM) (15), both hENT1 and hCNT1 are
unlikely to be saturated.
|
The reabsorption of adenosine by the kidney is an important mechanism for regulation of the pharmacological activity of adenosine in the kidney. As reviewed by Jackson and Dubey (19), adenosine regulates preglomerular and postglomerular vascular resistances, glomerular filtration rate, rennin release, epithelial transport, and intrarenal inflammation. If other nucleoside transporters are present in the kidney epithelial cells, they too may influence the renal disposition of this and other nucleosides. Transport experiments with kidney apical and basolateral membrane vesicles or with kidney cell lines have demonstrated only an ENT1 type of activity on the apical (9), basolateral (20), or both faces (10) of these epithelial cells. However, there is no evidence that an ENT2-type transporter is present in the kidney epithelial cells. Although hCNT2 was originally cloned from the human kidney, functional studies with brush border membrane vesicles from the human kidney have not detected hCNT2 activity, but these studies did find hCNT1-type activity that is inhibited by guanosine (6). Immunolocalization studies to determine the localization of hCNTs in the kidney epithelium have not been performed because of a lack of antibodies for such studies. However, even if hCNT2 is present on the brush border membrane of the kidney epithelium, the above findings will likely stand and possibly exaggerate the reabsorption and secretion of adenosine and deoxyadenosine, respectively. This is because adenosine is efficiently transported by hCNT2, whereas deoxyadenosine appears to be a poor permeant of hCNT2 (21).
In summary, we have shown for the first time, using fluorescent-labeled
proteins, that the concentrative and equilibrative transporters are
localized on the different faces of the polarized kidney epithelium
cell. This differential localization appears to be triggered by
differentiation and may explain the vectorial transport of
nucleosides and nucleoside drugs across the cell membrane. The
directionality of the vectorial transport will depend on the relative
affinity and maximal transport activity of the two transporters for the
nucleosides and nucleoside drugs and likely explains why some
nucleosides and nucleoside analogs are absorbed, whereas others are secreted.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Glenda Schneider for technical assistance, Dhruba SenGupta for experimental advice, and Paulette Brunner for initial help with using the confocal microscope of the W. M. Keck Center for Advanced Studies in Neural Signaling.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant RO1GM54447.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Dept. of Pharmaceutics, Box 357610, University of Washington, Seattle, WA 98195. Tel.: 206-543-9434; Fax: 206-543-3204; E-mail: jash@u.washington.edu.
Published, JBC Papers in Press, July 3, 2002, DOI 10.1074/jbc.M204986200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: NT, nucleoside transporter; hCNT, human concentrative nucleoside transporter; hENT, human equilibrative nucleoside transporter; NBMPR, nitrobenzylthioinosine; MDCK cells, Madin-Darby canine kidney cells; CFP, cyan fluorescent protein; YFP, yellow fluorescent protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Griffith, D. A., and Jarvis, S. M. (1996) Biochim. Biophys. Acta 1286, 153-181[Medline] [Order article via Infotrieve] |
| 2. |
Vijayalakshmi, D.,
and Belt, J. A.
(1988)
J. Biol. Chem.
263,
19419-19423 |
| 3. |
Patil, S. D.,
and Unadkat, J. D.
(1997)
Am. J. Physiol.
272,
G1314-G1320 |
| 4. | Ward, J. L., and Tse, C. M. (1999) Biochim. Biophys. Acta 1419, 15-22[Medline] [Order article via Infotrieve] |
| 5. |
Ward, J. L.,
Sherali, A., Mo, Z. P.,
and Tse, C. M.
(2000)
J. Biol. Chem.
275,
8375-8381 |
| 6. | Gutierrez, M. M., Brett, C. M., Ott, R. J., Hui, A. C., and Giacomini, K. M. (1992) Biochim. Biophys. Acta 1105, 1-9[Medline] [Order article via Infotrieve] |
| 7. | Franco, R., Centelles, J. J., and Kinne, R. K. (1990) Biochim. Biophys. Acta 1024, 241-248[Medline] [Order article via Infotrieve] |
| 8. | Chandrasena, G., Giltay, R., Patil, S. D., Bakken, A., and Unadkat, J. D. (1997) Biochem. Pharmacol. 53, 1909-1918[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Trimble, M. E., and Coulson, R. (1984) Am. J. Physiol. 246, F794-F803 |
| 10. | Doherty, A. J., and Jarvis, S. M. (1993) Biochim. Biophys. Acta 1147, 214-222[Medline] [Order article via Infotrieve] |
| 11. | Lum, P. Y., Ngo, L. Y., Bakken, A. H., and Unadkat, J. D. (2000) Cancer Chemother. Pharmacol. 45, 273-278[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Mangravite, L. M.,
Lipschutz, J. H.,
Mostov, K. E.,
and Giacomini, K. M.
(2001)
Am. J. Physiol.
280,
F879-F885 |
| 13. | Kuttesch, J. F., Jr., and Nelson, J. A. (1982) Cancer Chemother. Pharmacol. 8, 221-229[Medline] [Order article via Infotrieve] |
| 14. | Nelson, J. A., Vidale, E., and Enigbokan, M. (1988) Drug Metab. Dispos. 16, 789-792[Abstract] |
| 15. | Nelson, J. A., Kuttesch, J. R., Jr., and Herbert, B. H. (1983) Biochem. Pharmacol. 32, 2323-2327[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Kuttesch, J. F., Jr., Robins, M. J., and Nelson, J. A. (1982) Biochem. Pharmacol 31, 3387-3394[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Ritzel, M. W. L.,
Yao, S. Y. M.,
Huang, M. Y.,
Elliott, J. F.,
Cass, C. E.,
and Young, J. D.
(1997)
Am. J. Physiol.
272,
C707-C714 |
| 18. | Ritzel, M. W., Yao, S. Y., Huang, M. Y., Elliott, J. F., Cass, C. E., and Young, J. D. (1997) Am. J. Physiol. 272, C707-C714 |
| 19. |
Jackson, E. K.,
and Dubey, R. K.
(2001)
Am. J. Physiol.
281,
F597-F612 |
| 20. | Williams, T., Doherty, A., Griffith, D., and Jarvis, S. (1989) Biochem. J. 264, 223-231[Medline] [Order article via Infotrieve] |
| 21. |
Schaner, M. E.,
Wang, J.,
Zhang, L., Su, S. F.,
Gerstin, K. M.,
and Giacomini, K. M.
(1999)
J. Pharmacol. Exp. Ther.
289,
1487-1491 |
This article has been cited by other articles:
![]() |
R. Govindarajan, A. H. Bakken, K. L. Hudkins, Y. Lai, F. J. Casado, M. Pastor-Anglada, C.-M. Tse, J. Hayashi, and J. D. Unadkat In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1809 - R1822. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Errasti-Murugarren, M. Pastor-Anglada, and F. J. Casado Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs J. Physiol., August 1, 2007; 582(3): 1249 - 1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Damaraju, A. N. Elwi, C. Hunter, P. Carpenter, C. Santos, G. M. Barron, X. Sun, S. A. Baldwin, J. D. Young, J. R. Mackey, et al. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney Am J Physiol Renal Physiol, July 1, 2007; 293(1): F200 - F211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Hosseini, J. J. Kohler, C. P. Haase, N. Tioleco, T. Stuart, E. Keebaugh, T. Ludaway, R. Russ, E. Green, R. Long, et al. Targeted Transgenic Overexpression of Mitochondrial Thymidine Kinase (TK2) Alters Mitochondrial DNA (mtDNA) and Mitochondrial Polypeptide Abundance: Transgenic TK2, mtDNA, and Antiretrovirals Am. J. Pathol., March 1, 2007; 170(3): 865 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhou, L. Xia, K. Engel, and J. Wang Molecular Determinants of Substrate Selectivity of a Novel Organic Cation Transporter (PMAT) in the SLC29 Family J. Biol. Chem., February 2, 2007; 282(5): 3188 - 3195. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xia, K. Engel, M. Zhou, and J. Wang Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells Am J Physiol Renal Physiol, February 1, 2007; 292(2): F682 - F690. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-W. Lee, Y. Lai, H. Zhang, and J. D. Unadkat Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1): IMPLICATIONS FOR INTERSPECIES DIFFERENCES IN MITOCHONDRIAL TOXICITY OF FIALURIDINE J. Biol. Chem., June 16, 2006; 281(24): 16700 - 16706. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Aymerich, F. Foufelle, P. Ferre, F. J. Casado, and M. Pastor-Anglada Extracellular adenosine activates AMP-dependent protein kinase (AMPK) J. Cell Sci., April 15, 2006; 119(8): 1612 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lai, E.-W. Lee, C. C. Ton, S. Vijay, H. Zhang, and J. D. Unadkat Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively Am J Physiol Cell Physiol, January 1, 2005; 288(1): C39 - C45. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Aymerich, M. Pastor-Anglada, and F. J. Casado Long Term Endocrine Regulation of Nucleoside Transporters in Rat Intestinal Epithelial Cells J. Gen. Physiol., October 25, 2004; 124(5): 505 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chang, P. W. Swaan, L. Y. Ngo, P. Y. Lum, S. D. Patil, and J. D. Unadkat Molecular Requirements of the Human Nucleoside Transporters hCNT1, hCNT2, and hENT1 Mol. Pharmacol., March 1, 2004; 65(3): 558 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chaudary, Z. Naydenova, I. Shuralyova, and I. R Coe Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1 Cardiovasc Res, March 1, 2004; 61(4): 780 - 788. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lai, C.-M. Tse, and J. D. Unadkat Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs J. Biol. Chem., February 6, 2004; 279(6): 4490 - 4497. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, F. Visser, M. F. Vickers, T. Lang, M. J. Robins, L. P.C. Nielsen, I. Nowak, S. A. Baldwin, J. D. Young, and C. E. Cass Uridine Binding Motifs of Human Concentrative Nucleoside Transporters 1 and 3 Produced in Saccharomyces cerevisiae Mol. Pharmacol., December 1, 2003; 64(6): 1512 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Mangravite, G. Xiao, and K. M. Giacomini Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells Am J Physiol Renal Physiol, May 1, 2003; 284(5): F902 - F910. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||